This website is intended for healthcare professionals only

Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Personalized and predictive dermatology recognizes that each patient is unique and aims to comprehensively address all aspects of an individual’s skin health. This approach tailors skin care treatments based on a combination of factors, including genetic and epigenetic profiles, skin type, microbiome composition and the exposome (an individual’s lifetime exposures).1 Scientists are exploring how ecological […]

Prof. Dédée Murrell introduces the Women’s Dermatologic Society (WDS) and its focus on mentorship, alongside an overview of the WDS EADV 2026 session and why it is worth exploring on demand.


Expert Insights EADV

Dedee Murrell drug repurposing in rare genetic skin diseasesThe Women’s Dermatologic Society (WDS) session helped open this year’s European Academy of Dermatology and Venereology (EADV) Congress, bringing together expert faculty to discuss advances and emerging trends across medical dermatology.

Chaired by Dr Cheryl Rosen (Toronto Western Hospital, Toronto, Canada) and Prof. Dédée Murrell (St George Hospital, University of NSW, Sydney, Australia), the session featured short, 10-minute presentations from a selection of invited experts from across the globe covering new research and developments on topics ranging from blistering diseases and skin cancer to scarring alopecias, tropical diseases, and pediatric pigmentary disorders.

Following the session, we caught up with touchDERMATOLOGY Editorial Board member and session co-chair Prof. Dédée Murrell to learn more about the WDS, its session at EADV 2026, why it is worth watching if you missed it, and why you should consider joining the society.


read more

Transcript:

Q. What is the WDS?

The Women’s Dermatology Society, or WDS, was founded just over 50 years ago. It is an international organization headquartered in the USA, with branches and members in Europe, India, and South Africa. About 10% of its members are men, while the majority, as you would expect, are women. The main purpose of the group is to help younger people with their careers through mentoring, developing leadership skills, and supporting each other; it is a big family.

It is one of the few organizations whose main focus is mentorship and career development, showing people how they can have a successful career, be a mother, and have a family life.

Q. What were your highlights from the WDS session at EADV26?

This year’s meeting was packed out. Last year, when we held the meeting in Paris, it was also among the top 10 most popular sessions watched online after the meeting.

Yesterday, we had stars of the WDS from around the world speaking on their areas of expertise, ranging from medical and cosmetic dermatology to pediatric dermatology, tropical diseases, and unmet needs. You can watch the session afterwards, and it will be very educational for you and your residents.

Q. Why join the WDS?

Membership is free for residents and very inexpensive for others. International members can join as e-members. Most events take place at the American Academy of Dermatology (AAD) meeting. The society also holds an industry visioning meeting in the USA, separate from the AAD meeting. So, think about coming along when you attend the AAD meeting.

Next year in Guadalajara, Mexico [at the 26th World Congress of Dermatology 2027 congress], we’re going to have a special leadership day for women held by the Women’s Dermatology Society the day before the meeting, as well as a big social event. So, join us.

Note: This transcript has been lightly edited to ensure clarity.


Exploring the WDS session at EADV 2026

What could you take away from this year’s WDS session? This session is certainly one to watch. Below, we outline the key themes from each presentation, from diagnostic challenges to evolving treatment approaches, to help you choose what to explore on demand.


Blistering diseases in pregnancy

Prof. Aikaterini Patsatsi (Thessaloniki, Greece), co-chair of the EADV Blistering Diseases Task Force, opened this year’s WDS session at EADV 2026 with a focus on blistering diseases in pregnancy. She explored the recognition and diagnosis of pemphigoid gestationis, treatment escalation, and options for refractory disease. She highlighted the importance of early intervention and adequate treatment for pregnancy outcomes, before discussing neonatal pemphigus, planning for conception in patients with pemphigus, and other considerations for optimizing patient care.


Scabies update

Shifting the focus to scabies, Prof. Carmen Maria Salavastru (Bucharest, Romania), pediatric dermatologist and President-elect of EADV, explored advances in epidemiology, diagnosis, and management. She addressed challenges including the increasing burden of disease, institutional outbreaks, diagnostic difficulties, and treatment choices. Her presentation emphasized translating the latest evidence into clinical practice to support earlier diagnosis, more effective treatment regimens, and improved disease control.


Hedgehog inhibitors neoadjuvant treatment in skin cancer surgery

Reducing tumor burden before surgery is an important consideration in locally advanced basal cell carcinoma (BCC). Dr Stamatina Verykiou (Limassol, Cyprus) explored the role of Hedgehog inhibitors in this setting. She outlined current treatment options and the rationale for targeting the Hedgehog signaling pathway, alongside treatment limitations. Drawing on study data and cases from her own practice, she reviewed the evidence to date for vismodegib and sonidegib in BCC, before considering outstanding questions around treatment duration and dosing.


Update on bullous pemphigoid

Dr Snejina Vassileva (Sofia, Bulgaria), a leading expert in bullous diseases and an active contributor to the WDS and its journal, the International Journal of Women’s Dermatology, joined us for an update on bullous pemphigoid. She reviewed the epidemiology of this condition, which predominantly affects older adults, exploring its increasing prevalence in Europe and the possible reasons behind this trend. Her presentation covered typical and atypical presentations, including nonbullous pemphigoid, alongside potential drug triggers and established and emerging approaches to diagnosis and treatment. She also discussed advances in understanding disease pathogenesis, including the role of type 2 inflammation, and how these are informing emerging targeted therapies that could shape future management.


Managing scarring alopecias

Early recognition and intervention were central to the next presentation, as Dr Anastasia Therianou (London, UK), EADV Communications Committee member, explored the management of four scarring alopecias: frontal fibrosing alopecia, lichen planopilaris, folliculitis decalvans, and discoid lupus erythematosus. She discussed diagnostic features, disease monitoring, and treatment pathways, alongside emerging therapies and other considerations, emphasizing the need to halt progression before irreversible follicular destruction occurs. Her presentation also highlighted the importance of treating the whole patient, with symptom control, eyebrow involvement, camouflage, and cosmetic rehabilitation all forming part of successful management.


Neglected tropical diseases in 2026

Traveling from Santo Domingo, Dominican Republic, to join the session, Dr Mariel Amelia Isa Pimentel, Secretary General of the International League of Dermatological Societies (ILDS), explored the challenges facing neglected tropical diseases in 2026. She focused on chromomycosis, mycetoma, rhinoentomophthoromycosis, and leprosy, examining how climate change, geographical isolation, and limited access to healthcare contribute to the burden of these often underrecognized conditions. Through case studies, she reviewed developments and challenges in diagnosis and treatment, closing with a call for earlier recognition, improved diagnosis, stronger evidence, and better access to effective therapies.


Acquired pigmentary disorders in children

The WDS session concluded with Prof. Rashmi Sarkar (Noida, Uttar Pradesh, India), a pediatric dermatologist and longstanding WDS member, discussing acquired pigmentary disorders in children. She explored the causes of hyperpigmentation, covering conditions including erythema dyschromicum perstans, lichen planus pigmentosus, acanthosis nigricans, actinic lichen planus, and pellagra. Through case reports, she highlighted their clinical and histopathological features, diagnostic clues, helping attendees distinguish between conditions that can present with similar pigmentary change and ultimately the best management and treatment options.


From diagnostic challenges to emerging treatments, the WDS session offered practical learning across a broad range of dermatological conditions. Revisit the presentations on the EADV virtual on demand platform to explore the topics most relevant to your practice. For those interested in the society’s wider work, Prof. Murrell’s invitation also offers a reason to explore how WDS membership could support your career through mentorship, leadership development, and international connections.


Cite: The Women’s Dermatologic Society at EADV 2026. touchDERMATOLOGY. October 28 2026.

Disclosure: No funding was received for the publication of this content. Thank you to Prof. Murrell for sharing her expert insights. Prof. Murrell discloses relationships with AbbVie, Almirall, Amgen, Amicus, Amryt, AnaptysBio, Arcutis, Arena, argenx, Aslan, AstraZeneca, BMS, Botanix, Castle Creek, Celgene, Chiesi, Dermavant, Dermira, Evelo Biosciences, Galderma, GSK, Incyte, Janssen, Kiniksa, Krystal Biotech, LEO Pharma, Lilly, L’Oréal, MedImmune, Merck, Nektar Therapeutics, Novartis, Ono Pharma, Palleon, Pierre Fabre, Pfizer, Principia Bio, RAPT Therapeutics, Regeneron–Sanofi, Rheacell, Roche, Sun Pharma, Takeda, and UCB.

Editor: Gina Furnival, Head of Content

touchDERMATOLOGY coverage of EADV 2026: This content has been developed independently by Touch Medical Media for touchDERMATOLOGY. touchDERMATOLOGY was an official media partner of the EADV Congress 2026. touchDERMATOLOGY is not affiliated with the EADV. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Open Nav
touchConference Hub
Section 2 of 3 Part 5 of 9

touchDERMATOLOGY coverage of EADV Congress 2026

Prev Part
Next Part
touchConference Hub

touchDERMATOLOGY coverage of EADV Congress 2026

Late-breaking data

Further APEX data supports zumilokibart's potential as a less frequent dosing biologic option for atopic dermatitis; Melinda Gooderham
Further APEX data supports zumilokibart's potential as a less frequent dosing biologic option for atopic dermatitis; Melinda Gooderham

Further APEX data supports zumilokibart’s potential as a less frequent dosing option for atopic dermatitis

Part B of the phase 2 APEX trial evaluated three zumilokibart dosing regimens in adults with moderate-to-severe atopic dermatitis. All three met the primary endpoint at Week 16, with findings supporting mid dose selection for phase 3. Dr Melinda Gooderham discusses the efficacy and safety results from both Part A and Part B and what they could mean for clinical practice and those living with AD.
Abdakibart in hidradenitis suppurativa: What we learned from LOTUS; Martina Porter
Abdakibart in hidradenitis suppurativa: What we learned from LOTUS; Martina Porter

Abdakibart in hidradenitis suppurativa: What we learned from LOTUS

Could abdakibart offer a new treatment option for hidradenitis suppurativa? Dr Martina L. Porter discusses encouraging findings from the phase 2 LOTUS trial, including improvements in disease severity and draining tunnels, alongside a reassuring safety profile over 16 weeks, and considers what these results could mean for clinical practice.
Safety of dupilumab in pregnancy explored in final registry results
Safety of dupilumab in pregnancy explored in final registry results

Safety of dupilumab in pregnancy explored in final registry results

For women taking dupilumab to manage atopic dermatitis or asthma, limited pregnancy safety data can make treatment decisions challenging. Dr Christina Chambers discusses reassuring findings from a registry study of 539 pregnancies and how they could help clinicians counsel women who are pregnant or planning a family.

JAKPPPOT investigates the feasibility of a definitive JAKi trial in palmoplantar pustulosis

Encouraging findings from JAKPPPOT support the feasibility of a definitive randomized controlled trial of Janus kinase inhibitors in palmoplantar pustulosis and provide an exploratory estimate of treatment effect. We spoke with Dr David Gleeson about the results presented at EADV 2026 and their implications for future research.
0 mins

Topical RLS-1496 reduces actinic keratosis lesion counts

RLS-1496 1% cream is an investigational senotherapeutic treatment that inhibits GPX4. It aims to target senescent cells, potentially offering a new approach to treating actinic keratosis (AK). Encouraging findings from a phase 1b/2a, multicenter, open-label study were presented at EADV 2026. We spoke with Dr Mary Spellman, who presented the findings, about the results and their implications for the treatment’s future development.
Show All...
Currently viewing

Expert insights

Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial
Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial

Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial

Sonelokimab showed encouraging results in the phase 2 LEDA trial in adults with palmoplantar pustulosis. Dr Nina Magnolo discusses the findings, including a mean 64% reduction in disease severity at Week 16, and their potential implications for patients.
Mario Valenti, bimekizumab in hidradenitis suppurativa
Mario Valenti, bimekizumab in hidradenitis suppurativa

Real-world outcomes of bimekizumab in hidradenitis suppurativa

How does bimekizumab perform in everyday clinical practice? An Italian multicenter study reported improvements in disease activity, pain, and quality of life in people with hidradenitis suppurativa, with no unexpected safety signals. Dr Mario Valenti shares the findings and his perspective with touchDERMATOLOGY.
Prof. Dédée Murrell; The Women’s Dermatologic Society
Prof. Dédée Murrell; The Women’s Dermatologic Society

Drug repurposing to advance treatment for rare genetic skin diseases

Drug repurposing could offer new treatment opportunities for rare genetic skin diseases. Prof. Dédée Murrell discusses the rationale for exploring existing medicines, progress in epidermolysis bullosa, and how a new trial aims to match treatments to patients’ inflammatory profiles rather than their genetic subtype.
Maria-Angeliki Gkini
Maria-Angeliki Gkini

EADV 2026: Psoriasis highlights and implications for clinical practice

On Day 2 of the EADV 2026 congress, we were delighted to speak with touchDERMATOLOGY Editorial Board member, Dr Maria Angeliki Gkini who shared her highlights from key psoriasis sessions and discussed what these developments could mean for clinical practice.
Prof. Dédée Murrell; The Women’s Dermatologic Society
Prof. Dédée Murrell; The Women’s Dermatologic Society

The Women’s Dermatologic Society at EADV 2026

What did the Women’s Dermatologic Society bring to EADV 2026? Explore session highlights spanning blistering diseases, skin cancer, scarring alopecias, and more. Prof. Dedee Murrell introduces the society’s focus on mentorship, explains why the session is worth watching, and shares why dermatologists should consider joining.

Could rezpegaldesleukin offer long-term remission in atopic dermatitis?

New 52-week REZOLVE-AD data showed durable responses with monthly and quarterly rezpegaldesleukin (REZPEG) maintenance dosing in atopic dermatitis. Prof. Thomas Bieber discusses the findings and the potential for long-term remission and disease modification, highlighting the further evidence needed to explore these goals.
Dr Melinda Gooderham reflects on her EADV 2026 highlights, including updates in JAKi, zasocitinib vs. deucravacitinib, and the ICONIC-TOTAL findings on icotrokinra in psoriasis.
Dr Melinda Gooderham reflects on her EADV 2026 highlights, including updates in JAKi, zasocitinib vs. deucravacitinib, and the ICONIC-TOTAL findings on icotrokinra in psoriasis.

EADV 2026 highlights with Dr Melinda Gooderham

What were the key dermatology updates at EADV 2026? Dr Melinda Gooderham shares her highlights, exploring the Janus kinase (JAK) inhibitors session, new data comparing zasocitinib with deucravacitinib, and 2-year findings from ICONIC-TOTAL evaluating icotrokinra.
Ashraf Badawi
Ashraf Badawi

Key updates in the field of laser and energy-based devices

From pruritus and burn scars to cutaneous neurofibromas, Prof. Ashraf Badawi explores some of the new directions for lasers and energy-based devices discussed at this years EADV congress.

Study links glucagon-like peptide-1 receptor agonist use with nail disorders

Could glucagon-like peptide-1 receptor agonists affect nail health? A multinational study presented at EADV 2026 found nail disorders were reported more frequently among users, with nearly sevenfold higher odds of nail detachment. Prof. Bianca Maria Piraccini discusses the findings and why further clinical assessment is needed.
Show All...

News

3 mins

touchDERMATOLOGY announces new media partnership with the EADV Congress

Through our new collaboration, we will work together to increase the visibility of important developments in dermatology, from the latest clinical research and scientific advances to key society news and updates. As part of the partnership, touchDERMATOLOGY will also bring our community independent coverage directly from the EADV Congress, including the latest data, expert perspectives, key clinical takeaways and onsite interviews with leading specialists.
3 mins

Your quick guide to keynote and plenary sessions at EADV 2026

With EADV Congress 2026 just around the corner, there is plenty to look forward to in Vienna from 30 September to 3 October. If you are joining this year, whether onsite or online, the keynote and plenary sessions are well worth making time for in your congress schedule.

Day 1: Late breakers, JAK inhibitors and keynote lecture open EADV 2026

The EADV Congress opens in Vienna on Wednesday, 30 September. Day 1 highlights include a midday plenary, two late-breaking sessions, a focus on JAK inhibitors, and a closing keynote on the COVID-19 pandemic and the infodemic.
Close Popup